...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental pharmacology & physiology >Effects of the endocannabinoid transport inhibitors AM404 and UCM707 on diabetic neuropathy in rats.
【24h】

Effects of the endocannabinoid transport inhibitors AM404 and UCM707 on diabetic neuropathy in rats.

机译：内源性大麻素转运抑制剂AM404和UCM707对大鼠糖尿病性神经病的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

1. Diabetic rats display increased pain responses following injection of formalin into the paw, suggesting the presence of hyperalgesia. In the present study, we investigated the efficacy of the systemic administration of the endocannabinoid transport inhibitors UCM707 and AM404 (1, 10 and 50 mg/kg, i.p.) on hyperalgesia during the formalin test in streptozocin (STZ)-induced diabetic rats. 2. Nociceptive testing was performed in male adult Wistar rats 4 weeks after the onset of hyperglycaemia. At the end of the experiment, all rats were weighed and then underwent plasma glucose measurements. 3. Diabetes caused significant hyperalgesia during both phases of the formalin test. At 10 and 50 mg/kg, both UCM707 and AM404 reversed chemical hyperalgesia in diabetic rats. UCM707 (10 and 50 mg/kg) caused less intensive nociceptive behaviour during both phases of the test, whereas AM404 (10 and 50 mg/kg) only affected pain scores during Phase 1 of the formalin test. At 1 mg, neither drug had any effect on pain behaviour in control and diabetic groups compared with their respective controls. Neither UCM707 nor AM404 had any effect on bodyweight or plasma glucose levels of treated compared with non-treated rats at any of the doses tested. 4. The results of the present study indicate that systemic administration of UCM707 and AM404 is effective in ameliorating chemical hyperalgesia in STZ-diabetic rats. Thus, endocannabinoid transport inhibitors may have potential in the treatment of painful diabetic neuropathy.
机译：1.糖尿病大鼠将福尔马林注射入爪后，疼痛反应增强，表明存在痛觉过敏。在本研究中，我们研究了链脲佐菌素（STZ）诱导的糖尿病大鼠在福尔马林测试期间内源性大麻素转运抑制剂UCM707和AM404（1、10和50 mg / kg，腹腔注射）对痛觉过敏的全身性治疗作用。 2.高血糖发作后4周，在雄性成年Wistar大鼠中进行伤害测试。实验结束时，对所有大鼠称重，然后进行血浆葡萄糖测量。 3.在福尔马林测试的两个阶段中，糖尿病均引起明显的痛觉过敏。在10和50 mg / kg时，UCM707和AM404均可逆转糖尿病大鼠的化学痛觉过敏。在测试的两个阶段中，UCM707（10和50 mg / kg）引起的强烈伤害感受行为，而AM404（10和50 mg / kg）仅在福尔马林测试的第一阶段影响疼痛评分。与对照组相比，在1 mg时，这两种药物对对照组和糖尿病组的疼痛行为均无影响。在任何测试剂量下，与未治疗的大鼠相比，UCM707和AM404都不会对治疗后的体重或血浆葡萄糖水平产生任何影响。 4.本研究的结果表明，UCM707和AM404的全身性给药可有效改善STZ糖尿病大鼠的化学痛觉过敏。因此，内源性大麻素转运抑制剂可能在治疗糖尿病性神经病变方面具有潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号